Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint
inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy …

Introduction: To date, tissue biopsy represents the gold standard for characterizing non-
small-cell lung cancer (NSCLC), however, the complex architecture of the disease has …

The use of FDA-approved drugs for the therapy of lung cancer through drug repurposing is a
noteworthy approach. We retrieved all the FDA-approved triazole-based drugs from …

Lung adenocarcinoma (LUAD) is the most common lung cancer, with high mortality. As a
tumor-suppressor gene, JWA plays an important role in blocking pan-tumor progression …

The role of N7-methylguanosine (m7G)-related miRNAs in lung adenocarcinoma (LUAD)
remains unclear. We used LUAD data from The Cancer Genome Atlas (TCGA) to establish a …

Pancreatic ductal adenocarcinoma (PDAC) poses significant challenges in terms of
prognosis and treatment. Recent research has identified splicing deregulation as a new …

Temozolomide (TMZ) is the first line of chemotherapy to treat primary brain tumors of the
type glioblastoma multiforme (GBM). TMZ resistance (TMZR) is one of the main barriers to …

Simple Summary Lung cancer is the most commonly diagnosed and most lethal cancer.
Since healthcare outcomes have improved with the advent of targeted therapy, it is …

Thoracic malignancies are associated with a substantial public health burden. Lung cancer
is the leading cause of cancer-related mortality worldwide, with significant impact on …

Introduction: Lung cancer remains a global health concern, with non-small cell lung cancer
(NSCLC) comprising the majority of cases. Early detection of lung cancer has led to an …